Cambiogenplasmid Explained

Drug Name:	Cambiogenplasmid
Gt Target Gene:	VEGF
Gt Vector:	Plasmid
Tradename:	Neovasculgen
Routes Of Administration:	Intraneural injection
Cas Number:	1540077-18-6
Atc Prefix:	V03
Atc Suffix:	AX
Chemspiderid:	none
Synonyms:	Pl-VEGF165

Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF).^{[1] [2]} Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.^{[3] [4]} It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.

See also

• Therapeutic angiogenesis

Notes and References

1. Web site: Adis Insight . Vascular endothelial growth factor gene therapy - HSCI . Springer Nature Switzerland AG .
2. News: Gene Therapy for PAD Approved. https://web.archive.org/web/20150903230011/http://www.dddmag.com/news/2011/12/gene-therapy-pad-approved . 3 September 2015 . Drug Discovery and Development . 6 December 2011. 5 August 2015.
3. Web site: Eurolab . Neovasculogen listing in Eurolab . 4 August 2015 .
4. Deev RV, Bozo IY, Mzhavanadze ND, Voronov DA, Gavrilenko AV, Chervyakov YV, Staroverov IN, Kalinin RE, Shvalb PG, Isaev AA . 6 . pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia . Journal of Cardiovascular Pharmacology and Therapeutics . 20 . 5 . 473–82 . September 2015 . 25770117 . 10.1177/1074248415574336 . 13443907 .